timarbaev / iStockphoto.com
Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office (EUIPO) that an applied-for trademark would be confused with its own earlier-registered mark.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda Pharmaceutical, Nikken International, Kenzen, European Union Intellectual Property Office, trademark opposition, cardiovascular